Ursolic acid nanoliposomal - Liyuanheng Pharmaceutical

Drug Profile

Ursolic acid nanoliposomal - Liyuanheng Pharmaceutical

Latest Information Update: 26 May 2016

Price : $50

At a glance

  • Originator Liyuanheng Pharmaceutical
  • Developer Liyuanheng Pharmaceutical; Tianjin Medical University Cancer Institute and Hospital
  • Class Anti-inflammatories; Antineoplastics
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 26 May 2016 Chemical information added
  • 23 May 2016 Phase-I development is ongoing in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top